Parabilis Medicines, Inc. PBLS
27.75 USD -1.90 (-6.42%)
Nov 12, 2026, 10:13 AM EST
27.93 Day range 29.88
22.66 52-week range 42.49
- YTD
- -12.20%
- 1 year
- -12.20%
News
benzinga.com Parabilis Medicines Q3 EPS $(0.36), Inline, Sales $2.114M Beat $375.000K Estimate Parabilis Medicines (NASDAQ:PBLS) reported quarterly losses of $(0.36) per share which met the analyst consensus estimate. This is a 98.34 percent increase over losses of $(21.66) per share from the…
globenewswire.com Parabilis Medicines Reports Third Quarter 2026 Financial Results and Provides Business Updates Presented updated Phase 1/2 data at ESMO Congress 2026 demonstrating a 72.2% objective response rate at the 32-week landmark and a favorable safety and tolerability profile for zolucatetide in…
benzinga.com Canaccord Genuity Initiates Coverage On Parabilis Medicines with Buy Rating, Announces Price Target of $39 Canaccord Genuity analyst John Newman initiates coverage on Parabilis Medicines (NASDAQ:PBLS) with a Buy rating and announces Price Target of $39.
benzinga.com HC Wainwright & Co. Initiates Coverage On Parabilis Medicines with Buy Rating, Announces Price Target of $40 HC Wainwright & Co. initiates coverage on Parabilis Medicines (NASDAQ:PBLS) with a Buy rating and announces Price Target of $40.
benzinga.com Silence Therapeutics, Disc Medicine, Veradermics And Other Big Stocks Moving Higher On Monday U.S. stocks mixed as Dow fell ~100 points; Silence Therapeutics surged 125.7% on Merck KGaA buyout, while biotech and tech shares gained.
benzinga.com Parabilis Medicines To Present Updated Clinical Data For Zolucatetide In Patients With Desmoid Tumors At ESMO Congress 2026 Oral presentation will include updated data from the ongoing Phase 1/2 trial, with dose optimization arm designed to inform dose and regimen selection for Phase 3 registrational trial in desmoid…
benzinga.com Parabilis Medicines Initiates Dose-Ranging Clinical Cohort Evaluating Zolucatetide In Patients With Familial Adenomatous Polyposis As Part Of Ongoing Phase 1/2 Clinical Trial New dose-ranging cohort in FAP builds on compelling early clinical evidence observed with zolucatetide in patients with FAP and concomitant desmoid tumorsZolucatetide directly inhibits β-catenin:TCF,…
benzinga.com Vicor, Arm Holdings, Micron Technology And Other Big Stocks Moving Higher On Thursday U.S. stocks rose; Vicor jumped 13.5% on a new license, while Generac surged 19.6% on an Amazon deal. Securitize and biotech shares rallied.
benzinga.com Parabilis Medicines Q2 EPS $(2.32) Misses $(0.08) Estimate, Sales $148.000K Miss $25.000M Estimate Parabilis Medicines (NASDAQ:PBLS) reported quarterly losses of $(2.32) per share which missed the analyst consensus estimate of $(0.08) by 2800 percent. This is a 89.59 percent increase over losses…- benzinga.com Leerink Partners Initiates Coverage On Parabilis Medicines with Outperform Rating, Announces Price Target of $40 Leerink Partners analyst Andrew Berens initiates coverage on Parabilis Medicines (NASDAQ:PBLS) with a Outperform rating and announces Price Target of $40.
benzinga.com This Parabilis Medicines Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Top Wall Street analysts changed outlook on top stocks. See full analyst rating changes & buy/sell recommendations for PBLS stock on Benzinga.- benzinga.com B of A Securities Initiates Coverage On Parabilis Medicines with Buy Rating, Announces Price Target of $45 B of A Securities analyst Tazeen Ahmad initiates coverage on Parabilis Medicines (NASDAQ:PBLS) with a Buy rating and announces Price Target of $45.